


4. (Amended) A compound having the general structure:




wherein R_1 , R_7 and R_8 are independently selected from the group consisting of H, halo, haloalkyl and hydroxy; and

R_3 is hydroxy or $-OCONH_2$], with the proviso that at least one of R_1 , R_7 and R_8 is other than H].


5. (Amended) The compound of claim 4 wherein R_7 and R_8 are H; R_1 is H or F; and R_3 is hydroxy or $-OCONH_2$.

6. (Amended) A method for treating a patient suffering from a neurological disorder, said method comprising the step of administering a composition comprising a compound [selected from the group consisting of] represented by the formula



wherein [R₁] R₇, R₈ and R₉ are independently selected from the group consisting of H, halo, alkyl, haloalkyl and hydroxy; and
 R₃ is hydroxy or -OCONH₂; and
 R₄ is hydroxy or carbonyl, with the proviso that when R₉ is H, R₇ and R₈ are not both H].

7. (Amended) The method of claim 6 wherein said compound has the general structure




wherein [R₁] R₉ is selected from the group consisting of H, halo, haloalkyl and hydroxy;
 and

R₃ is hydroxy or -OCONH₂.

8. (Amended) The method of claim 7 wherein [R₁] R₉ is H or halo; and
 R₃ is -OCONH₂.

9. (Amended) A method for preventing or limiting tissue damage resulting from an ischemic event [treating a patient suffering from tissue damage resulting from localized hypoxic conditions], said method comprising the step of administering a composition comprising a compound selected from the group consisting of




wherein [R₁,] R₇, R₈ and R₉ are independently selected from the group consisting of H, halo, alkyl, haloalkyl and hydroxy; and

R₃ is hydroxy or -OCONH₂]; and

R₄ is hydroxy or carbonyl, with the proviso that when R₉ is H, R₇ and R₈ are not both H.].


10. (Amended) The method of claim 9 wherein said compound has the general structure



wherein $[\text{R}_1]$ R_9 is selected from the group consisting of H, halo, haloalkyl and hydroxy; and R_3 is hydroxy or -OCONH_2 .

11. (Amended) The method of claim 10 wherein $[\text{R}_1]$ R_9 is H or halo; and R_3 is -OCONH_2 .
12. (Amended) The method of claim 9 wherein the [localized hypoxic condition] tissue damage is caused by cerebral ischemia.
13. (Amended) The method of claim 9 wherein the [localized hypoxic condition] tissue damage is caused by myocardial ischemia.

~~14~~¹¹. (Amended) A pharmaceutical composition comprising a compound selected from the group consisting of



wherein [R_1 ,] R_7 , R_8 and R_9 are independently selected from the group consisting of H, halo, alkyl, haloalkyl and hydroxy;



R_3 is hydroxy or $-OCONH_2$; and

[R_4 is hydroxy or carbonyl, with the proviso that when R_9 is H, R_7 and R_8 are not both H; and]

a pharmaceutically acceptable carrier[.].

~~15~~¹². (Amended) The composition of claim ~~14~~¹¹ wherein said compound has the general structure

A



wherein $[R_1]$ R_9 is selected from the group consisting of H, halo, haloalkyl and hydroxy; and
 R_3 is hydroxy or $-OCONH_2$.


13
~~16.~~ (Amended) The composition of claim 15 wherein $[R_1]$ R_9 is [selected from the group consisting of] halo[, haloalkyl and hydroxy].

17. (Amended) The composition of claim 15 wherein $[R_1]$ R_9 is H or F; and
 R_3 is $-OCONH_2$.

Please add new claims 18-27 as follows:

18. The composition of claim 15 wherein R_9 is H or F; and
 R_3 is hydroxy.

19. A compound having the general structure:



wherein R₁, R₇, R₈, R₉ and R₁₀ are independently selected from the group consisting of H, halo, alkyl, haloalkyl, -NR₅R₆, hydroxy, and alkoxy;

R₂ is F or Cl;

R₃ is hydroxy or -OCONH₂; and

R₅ and R₆ are independently C₁-C₄ alkyl.

20. The compound of claim 19 wherein
R₁ and R₇ are independently selected from the group consisting of H, halo, alkyl, haloalkyl, and hydroxy;

R₂ is F;

R₃ is hydroxy or -OCONH₂; and

R₈, R₉ and R₁₀ are H.

21. The compound of claim 19 wherein
R₁ and R₈ are independently selected from the group consisting of H, halo, alkyl, haloalkyl, and hydroxy;


R₂ is F;

R₃ is hydroxy or -OCONH₂; and

R₇, R₉ and R₁₀ are H.

22. The compound of claim 19 wherein
R₁ is selected from the group consisting of H, halo, alkyl, haloalkyl, and hydroxy;
R₂ is F;
R₃ is hydroxy or -OCONH₂; and
R₇, R₈, R₉ and R₁₀ are H.

23. The compound of claim 22 wherein R_1 is selected from the group consisting of H, F, Cl, CF_3 and hydroxy.
24. The compound of claim 23 wherein R_1 is F.
25. A pharmaceutical composition comprising the compound of claim 19 and a pharmaceutically acceptable carrier.
26. A pharmaceutical composition comprising the compound of claim 22 and a pharmaceutically acceptable carrier.
27. A method for reducing the incidence and severity of an epileptic seizure in an individual, said method comprising the step of administering to said individual a compound represented by the general structure:



wherein R_1 , R_7 and R_8 are independently selected from the group consisting of H, halo, alkyl, haloalkyl and hydroxy; and

R_3 is hydroxy or $-OCONH_2$.

28. The method of claim 27 wherein R_1 is H or F, and R_7 and R_8 are H.
29. The method of claim 28 wherein R_3 is $-OCONH_2$.